Advertisement

Drugs

, Volume 77, Issue 18, pp 2025–2036 | Cite as

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events

  • Zaina T. Al-Salama
  • Gillian M. Keating
  • Susan J. Keam
Adis Drug Evaluation

Abstract

Ticagrelor (Brilique®) is an orally administered P2Y12 inhibitor. A long-term (maintenance) regimen of ticagrelor 60 mg twice daily is indicated in the EU for coadministration with low-dose aspirin 75–150 mg/day for the secondary prevention of atherothrombotic events in high-risk patients with a history of myocardial infarction (MI) of at least 1 year. Approval is based on the results of the PEGASUS-TIMI 54 trial that compared ticagrelor with placebo (in conjunction with low-dose aspirin) in stable patients who had had a spontaneous MI 1–3 years prior to enrolment and were at high risk of atherothrombotic events. At 3 years, the composite primary efficacy endpoint of cardiovascular (CV) death, MI or stroke occurred in significantly fewer ticagrelor 60 mg twice daily than placebo recipients. Long-term ticagrelor had a manageable tolerability and safety profile. The risk of TIMI major bleeding (primary safety endpoint) was significantly increased in ticagrelor 60 mg twice daily versus placebo recipients; however, the risk appeared to decline after the first year of therapy. Landmark analyses have demonstrated that patients with a history of MI remain at a persistent high risk of the composite primary endpoint up to 5 years after the event. Furthermore, these analyses demonstrated that the efficacy of ticagrelor 60 mg twice daily was maintained over time, with less excess in bleeding after the first year. Thus, long-term dual antiplatelet therapy with ticagrelor 60 mg twice daily and low-dose aspirin is a valuable new option for the secondary prevention of atherothrombotic events in stable, high-risk patients with a history of MI of at least 1 year.

Notes

Acknowledgements

During the peer review process, the manufacturer of ticagrelor was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Zaina T. Al-Salama, Gillian M. Keating and Susan J. Keam are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/BB4CF06072661B7C.

References

  1. 1.
    Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25(14):1197–207.CrossRefPubMedGoogle Scholar
  2. 2.
    Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30–47.CrossRefPubMedGoogle Scholar
  3. 3.
    Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015;386(9990):292–302.CrossRefPubMedGoogle Scholar
  4. 4.
    European Medicines Agency. Brilique (ticagrelor) 60 mg film-coated tablets: EU summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 7 Nov 2017.
  5. 5.
    Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs. 2011;71(7):909–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Dhillon S. Ticagrelor: a review of its use in adults with acute coronary syndromes. Am J Cardiovasc Drugs. 2015;15(1):51–68.CrossRefPubMedGoogle Scholar
  7. 7.
    Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56(18):1456–62.CrossRefPubMedGoogle Scholar
  9. 9.
    Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol. 2016;67(10):1145–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Thomas MR, Angiolillo DJ, Bonaca MP, et al. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017;117(5):940–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–99.CrossRefPubMedGoogle Scholar
  12. 12.
    Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19(2):209–19.CrossRefPubMedGoogle Scholar
  13. 13.
    Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503–9.CrossRefPubMedGoogle Scholar
  14. 14.
    European Medicines Agency. Brilique (ticagrelor): EU assessment report. 2011. http://www.ema.europa.eu/. Accessed 7 Nov 2017.
  15. 15.
    Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61(7):723–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and patient outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011;108(11):1542–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185–93.CrossRefPubMedGoogle Scholar
  18. 18.
    Butler K, Wei C, Teng R. Single-dose ticagrelor does not prolong the QT interval in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(10):643–51.CrossRefPubMedGoogle Scholar
  19. 19.
    Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. Clin Pharmacokinet. 2015;54(11):1125–38.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Varenhorst C, Eriksson N, Johansson A, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol. 2012;68(8):1175–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Teng R, Muldowney S, Zhao Y, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects in hemodialysis and subjects with normal renal function [abstract plus poster P288]. In: 2017 ACCP annual meeting. 2017.Google Scholar
  23. 23.
    Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(3):477–87.CrossRefPubMedGoogle Scholar
  24. 24.
    Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol. 2013;69(4):877–83.CrossRefPubMedGoogle Scholar
  25. 25.
    Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800.CrossRefPubMedGoogle Scholar
  26. 26.
    Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014;167(4):437–444.e5.CrossRefPubMedGoogle Scholar
  27. 27.
    Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37(14):1133–42.CrossRefPubMedGoogle Scholar
  28. 28.
    Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732–40.CrossRefPubMedGoogle Scholar
  29. 29.
    Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67(23):2719–28.CrossRefPubMedGoogle Scholar
  30. 30.
    Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37(4):400–8.PubMedGoogle Scholar
  31. 31.
    Dellborg M, Bonaca MP, Storey R, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 [abstract no. P3670 plus poster]. Eur Heart J. 2017;38(Suppl 1):794–5.Google Scholar
  32. 32.
    Bonaca MP, Storey RF, Theroux P, et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017;70(11):1368–75.CrossRefPubMedGoogle Scholar
  33. 33.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.CrossRefPubMedGoogle Scholar
  34. 34.
    Euopean Medicines Agency. Plavix (clopidogrel) 75 mg film-coated tablets: EU summary of product characteristics. 2010. http://www.ema.europa.eu/. Accessed 7 Nov 2017.
  35. 35.
    European Medicines Agency. Effient (prasugrel) 5 mg film-coated tablets: EU summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 7 Nov 2017.
  36. 36.
    Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37(4):390–9.PubMedGoogle Scholar
  37. 37.
    Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.CrossRefPubMedGoogle Scholar
  38. 38.
    Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015;65(20):2211–21.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Valgimigli M, Bueno H, Byrne RA, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017.  https://doi.org/10.1093/eurheartj/ehx419.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Ibanez B, James S, Agewall S, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017.  https://doi.org/10.1093/eurheartj/ehx393.PubMedCrossRefGoogle Scholar
  42. 42.
    Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.CrossRefPubMedGoogle Scholar
  43. 43.
    Cosentino N, Campodonico J, Milazzo V, et al. 1-year risk stratification of patients with acute myocardial infarction according to the pegasus-timi 54 criteria [abstract no. P3639]. Eur Heart J. 2017;38(Suppl 1):784.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  • Zaina T. Al-Salama
    • 1
  • Gillian M. Keating
    • 1
  • Susan J. Keam
    • 1
  1. 1.SpringerAucklandNew Zealand

Personalised recommendations